Five posters to be presented including new long-term 36-month data from the ongoing X-TOLE OLE study of azetukalner in FOS and findings around ...

Phase 3 epilepsy program advancing with X-TOLE2 topline FOS data anticipated in H2 2025– Long-term azetukalner results from X-TOLE open-label ...

According to Future Market Insights (FMI), growing demand for rare gases across the globe for various applications is ...

Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Good afternoon, and thank you for standing by. At this time, I’d ...